Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Here come GMP Grade Cytokines！Free Sample is available！ Here come GMP Grade Cytokines！Free Sample is available！
5e5 of anti-CD22 CAR-293 cells were stained with 100 μL of 10 μg/mL of Alexa Fluor 488-Labeled Human Siglec-2, His Tag (Cat. No. SI2-HA2H7) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). Alexa 488 signal was used to evaluate the binding activity (QC tested).
Monoclonal Anti-Human Siglec-2 Antibody, Human IgG1 captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human Siglec-2 (176-687), His Tag (Cat. No. SI2-H52H8) with an affinity constant of 0.121 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Moxetumomab pasudotox | HA-22; GCR-8015; CAT-8015 | Approved | Astrazeneca Plc | Lumoxiti | United States | Leukemia, Hairy Cell | Innate Pharma | 2018-09-13 | Leukemia; Leukemia, Hairy Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Prolymphocytic; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Inotuzumab Ozogamicin | WAY-207294; PF-5208773; CMC-544 | Approved | Pfizer Inc, Ucb | Besponsa | Mainland China | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Pfizer Investment Co Ltd | 2017-06-28 | Lymphoma, B-Cell; Hematologic Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia; Lymphoma, Large B-Cell, Diffuse; Blast Crisis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Burkitt Lymphoma | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| RD-102 | RD-102 | Phase 1 Clinical | Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse | Details | |
| Anti-CD22 CAR T cell therapy (Shanghai GeneChem) | Phase 1 Clinical | Shanghai Genechem Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
| Anti-CD19 and anti-CD22 CAR T cell therapy (Seattle Children's Hospital) | Phase 1 Clinical | Seattle Children'S Hospital | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| Anti-CD22 CAR-T cell therapy (No. 307 Hospital) | Phase 2 Clinical | The Fifth Medical Center Of Pla General Hospital (Formerly 307 Hospital) | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| anti-CD22-CAR-transduced T cells（Southwest Hospital） | Phase 2 Clinical | Southwest Hospital | Leukemia; Lymphoma | Details | |
| Anti-CD22 CAR T cell therapy (Wuhan Bio-Raid) | Phase 1 Clinical | Wuhan Bio-Raid Biotechnology | Lymphoma, B-Cell; Multiple Myeloma | Details | |
| Anti-CD19/22-CAR vector-transduced T cell therapy (Chinese PLA General Hospital) | Phase 2 Clinical | People'S Liberation Army General Hospital Military Service | Leukemia; Lymphoma | Details | |
| CTA-101 | CTA-101 | Phase 1 Clinical | Nanjing Bioheng Biotech Co Ltd, Nanjing Medical University, Xuzhou Medical University (Xzmu) | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| CD19/CD22 dual-target CAR-T cell therapy (Shenzhen University General Hospital) | Phase 2 Clinical | Shenzhen University General Hospital | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| Anti-CD19 and anti-CD22 CAR-T cell therapy(IASO Biotherapeutics) | CT-120 | Phase 2 Clinical | Nanjing Iaso Biotherapeutics Co Ltd | Lymphoma, B-Cell; Leukemia, B-Cell; Lymphoma, Non-Hodgkin | Details |
| CD19x22 CAR T Cell Therapy (University Of Colorado Denver) | Phase 1 Clinical | University Of Colorado, Denver, Usa | Lymphoma, Non-Hodgkin | Details | |
| IMJ-995 | IMJ-995 | Novartis Pharma Ag | Details | ||
| CD22 CAR-T Cell Therapy (Hebei Senlang Biotechnology) | Hebei Senlang Biological Technology Co Ltd | Details | |||
| CD22-targeted CAR-T cell therapy (PersonGen Biomedicine) | Persongen Biotherapeutics | Details | |||
| BAY-1862864 | BAY-1862864 | Bayer AG | Details | ||
| Anti-CD22-CAR T cell therapy (Kecellitics Biotech) | Kecellitics Biotech Company Ltd | Details | |||
| Suciraslimab | SM-06; SM-03 | Phase 3 Clinical | Sinomab Bioscience Ltd | Arthritis, Rheumatoid; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin | Details |
| TRPH-222 | CD22-4AP; TRPH-222; CAT-02-106 | Catalent Inc | Details | ||
| bispecific CD19/CD22 CAR T-cell therapy （University of Colorado） | Phase 1 Clinical | University Of Colorado | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details | |
| CART22-cells | CART22-cells; JJO686 | Phase 1 Clinical | Novartis Pharma Ag, University Of Pennsylvania | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell | Details |
| CD19/CD22 dual-target CAR-T (Yake biotechnology) | Phase 2 Clinical | Shanghai YaKe Biotechnology Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| Anti-CD22/CD19 monoclonal antibody-toxin conjugate | Phase 1 Clinical | The University Of Texas Southwestern Medical Center | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| CD19-CD22 CAR-T cells (Shanghai Ultra-T Immune Therapeutics) | Phase 2 Clinical | Shanghai Ultra-T Immune Therapeutics Co LTD | Lymphoma, B-Cell; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell | Details | |
| Bispecific CD19/22 CAR T cells | Phase 2 Clinical | Lymphoma, Non-Hodgkin; Lymphoma | Details | ||
| Anti-CD19 anti-CD22 bispecific chimeric antigen receptor T cell therapy (Hrain Biotechnology) | Phase 1 Clinical | Hrain Biotechnology Co Ltd | Leukemia, Lymphoid | Details | |
| CAR-20-19-22 | CAR-20-19-22 | Phase 1 Clinical | The Medical College Of Wisconsin Nonprofit | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| CD19/22 Bi-specific CAR-T Cell Therapy(Shenzhen Geno-Immune Medical Institute) | 4SCAR19/22 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
| 4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) | 4SCAR-T | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Hematologic Neoplasms; Autoimmune Diseases; Neuroblastoma | Details |
| Chimeric antigen receptor T cell therapeutics (targeted CD19/CD20/CD22/CD30，Shanghai Unicar-Therapy Bio-medicine) | Phase 2 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Pancreatic Neoplasms; Lymphoma, Non-Hodgkin | Details | |
| JCAR-018 | JCAR-018 | Phase 1 Clinical | National Cancer Institute, Opus Bio | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
| CD20/CD22 dual Targeted CAR T-cell therapy (Zhejiang University) | Phase 1 Clinical | Zhejiang University, Shanghai YaKe Biotechnology Co Ltd | Hematologic Neoplasms | Details | |
| Anti-CD19/CD22 bispecific CAR-T cell therapy (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine) | Phase 1 Clinical | The Second Affiliated Hospital Of Henan University Of Traditional Chinese Medicine | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) therapy (KK Women's and Children's Hospital) | Phase 2 Clinical | Kk Women'S And Children'S Hospital | Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| UCART-22 | UCART-22 | Phase 1 Clinical | Cellectis Sa | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Dual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University) | Phase 1 Clinical | Stanford University, Orca Biosystems Inc | Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Leukemia, Lymphoid; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| GC-022 | GC-022; GC-022F | Phase 2 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Hematologic Neoplasms; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
| Anti-CD19/CD22 CAR-T cell therapy (Jiao Tong University) | Phase 1 Clinical | Shanghai Jiaotong University, Shanghai General Hospital | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| ThisCAR-T-22(Fundamenta Therapeutics) | ThisCAR-T-22 | Phase 1 Clinical | Fundamenta Therapeutics Ltd | Lymphoma, B-Cell | Details |
| Anti CD22 CAR-T cell therapy (Shanghai Yake Biotechnology) | Phase 2 Clinical | Shanghai YaKe Biotechnology Co Ltd, The First Affiliated Hospital Of Zhejiang University School Of Medicine, Beijing Gao Boren Hospital Co Ltd, Chengdu USino Technology Biology Co Ltd | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| JNJ-75348780 | Phase 1 Clinical | Janssen Research & Development Llc | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
| Anti-CD19 and anti-CD22 CAR T cell therapy (Hebei Senlang Biotechnology) | Phase 1 Clinical | Hebei Senlang Biological Technology Co Ltd | Leukemia, B-Cell | Details | |
| CD19/CD20 Dual CAR-T Cell Therapy (China Immunotech) | HX-s001; YTS101; HX-s001/YTS101; HXYT-001 | Phase 1 Clinical | Beijing Qingyi Taike Pharmaceutical Technology Co Ltd, China Immunotech Co Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Leukemia, B-Cell; Lymphoma, Non-Hodgkin | Details |
| CD19- and CD22 specific CAR (Seattle Children's Hospital) | Phase 1 Clinical | Seattle Children'S Hospital | Leukemia; Lymphoma | Details | |
| UCART-20x22 | UCART-20x22 | Phase 2 Clinical | Cellectis Sa | Lymphoma, Non-Hodgkin | Details |
| CD19/CD22 CAR-T cell therapy (Federal Research Institute of Pediatric Hematology, Oncology and Immunology) | Phase 2 Clinical | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Burkitt Lymphoma | Details | ||
| Autologous CD19/CD22 chimeric antigen receptor T-cell therapy (MD Anderson Cancer Center) | Phase 2 Clinical | The University Of Texas MD Anderson Cancer Center | Neoplasm, Residual; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
| Dual specificity CD19 and CD20 or CD22 CAR-T cell therapy(Chinese PLA General Hospital) | Phase 2 Clinical | Pla General Hospital | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
| SCRI-CAR22v2 | Phase 2 Clinical | Seattle Children'S Hospital | Leukemia; Lymphoma | Details | |
| Epratuzumab-cys-tesirine | ADCT-602 | Phase 2 Clinical | Adc Therapeutics Sa | Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell | Details |
This web search service is supported by Google Inc.
A-Z
